| Cost-effectiveness of rituximab in follicular lymphoma. | |
| | |
MedLine Citation:
|
PMID: 23140274 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
In advanced follicular lymphoma, rituximab is currently used with chemotherapy as induction therapy, and as maintenance monotherapy following induction in previously untreated patients and treatment-experienced relapsed/refractory patients. Herein, the authors characterize the clinical effectiveness, safety and cost-effectiveness of rituximab in follicular lymphoma, based on the literature review. Rituximab has a favorable safety profile and has been shown to improve progression-free survival, with some evidence of improvements to overall survival, particularly for relapsed/refractory patients. Rituximab has consistently been found to have a favorable economic profile, with cost per quality-adjusted life year falling within standard thresholds for cost-effectiveness. Challenges in cost-effectiveness analysis include the fact that life expectancy for patients with follicular lymphoma exceeds the period of available follow-up data and that treatment pathways are more complex than the model structures frequently used in oncology models. As data accrue and more complex models are developed, the cost-effectiveness of rituximab can be more accurately assessed. |
| | |
Authors:
|
Karissa M Johnston; Corneliu Bolbocean; Joseph Connors; Stuart Peacock |
Related Documents
:
|
6663664 - Cancer of the paranasal sinuses with particular reference to maxillary sinus cancer. 3972294 - Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up. 3341274 - Malignant submandibular gland tumors. a review of 91 patients. 23021204 - Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase i... 21265984 - High-intensity focused ultrasound as salvage therapy for patients with recurrent prosta... 20705564 - A phase ii trial of docetaxel with bevacizumab as first-line therapy for her2-negative ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-11 |
Journal Detail:
|
Title: Expert review of pharmacoeconomics & outcomes research Volume: - ISSN: 1744-8379 ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132257 Medline TA: Expert Rev Pharmacoecon Outcomes Res Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Attention deficit hyperactivity disorder, tic disorder, and allergy: Is there a link? A nationwide p...
Next Document: Synaptotagmin-like protein 4 and rab8 interact and increase dense granule release in platelets.